🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The GEOLynch Cohort Study

Recruitingn/aAges 18 Years - 80 YearsAllWageningen University
NCT03303833 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The GEOLynch cohort study has been established to investigate the influence of genetic, environmental and other factors on tumour risk in persons with Lynch syndrome.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Persons with a known mutation in a gene that causes Lynch syndrome, i.e. with an inherited monoallelic pathogenic germline mutation in either the MLH1, MSH2, MSH6, PMS2 or EPCAM gene. * Aged between 18 and 80 years at inclusion. Exclusion Criteria: * Additional carrier of another hereditary colon cancer predisposition syndrome (e.g. FAP) * (Chronic) Inflammatory bowel disease * Non-Dutch speaking * Dementia or another mental condition that makes it impossible to fill out questionnaires * Terminally ill persons
💊

What it tests

  • No intervention, observational study.
📍

Where

1 site
Wageningen University
Wageningen, Netherlands
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy